We have a ✨NEW PREPRINT✨! Using data from the @clscohorts.bsky.social Millennium Cohort Study and linked healthcare records, we tested the association between social media use and psychiatric diagnoses in secondary care in young people in England. This is still a work in progress - feedback welcome!
This is not to say no one experiences symptoms on discontinuation of antidepressants, but trial data don’t show us this and they are the best method we have to find a causal association between antidepressants cessation and symptoms.
Why would researchers want to inflate the problem? It’s probably both ideological and financial www.wired.com/story/taperi...
Certainly from trials we see there is a unique profile of discontinuation symptoms, but the clinical impact is far less than some researchers would have you believe.
Since Davies & Read review of 2019 Sameer Jauhar and I have been trying to get closer to the truth about AD discontinuation. It’s entered guidelines as FACT: 50% will experience difficulty stopping. So we completed the DEFINITITIVE meta-analysis of trial data.
jamanetwork.com/journals/jam...
The association between gabapentinoids and risk of self-harm is multifaceted: These findings do not support a direct effect of gabapentinoid treatment on self-harm but underscore the necessity for close patient monitoring throughout the gabapentinoid treatment journey www.bmj.com/content/389/...
Thanks for your interest in our study. I agree with your summary and the issues raised.
Metformin is recommended for antipsychotic associated weight gain. However, in >25k patients initiating antipsychotics, only 3.3% received metformin in the first 2 years. In this small group, it seems to work: patients lost 0.65% of their body weight vs. gaining 4.16% on antipsychotics alone.
What about the lack of spell checker for comments? Shows me how much of my typing is just mashing the keyboard.
FDA removes risk evaluation and mitigation for clozapine, including neutrophil monitoring www.fda.gov/drugs/postma...
This target trial emulation study of >25k patients finds no difference in total cholesterol at one year, but lower BMI and BP. And no difference in psychiatric hospital admission rates journals.plos.org/plosmedicine...
It’s generally agreed that aripiprazole conveys less cardiometabolic risk than the other, commonly prescribed, second gen antipsychotics, but that it’s potentially less effective. But there is a lack of evidence for this position.
New #datamind paper: physical health screening in people with severe mental illness in the UK is insufficient. Until it improves, it seems hard to see how we will move the needle on premature mortality in this population
“This is really quite a good programme” Joanna Moncrieff on ‘Nazi Propagantist’ Tucker Carlson.
“Unease”
Unfortunately a nuanced story is far less compelling than pitching this as a simple “good vs evil”.
Great work from @Alvin Richards-Belle et al.
High dose prescribing is more likely for: people with schizophrenia, minoritized ethic groups, younger people, men and people from more deprived areas
Figure showing prescription trends
If bipolar then it’s quetiapine:
Figure showing prescription trends
The patterns differ by diagnosis. If you have a schizophrenia, you are most likely to get olanzapine:
In the UK, 80% of antipsychotic prescribing is for one of 4 drugs: olanzapine, quetiapine, risperidone or aripiprazole
I stand by everything I've ever said on Twitter, so I've put it all here. Lets see how it fairs, shorn of any context. New material coming soon.
Hi there! Yes please
Is @altmetric a good enough reason to stay on X?
Like data science and health informatics for mental health? Come and work with us:
DOI: 10.4088/JCP.13m08978 and DOI: 10.4088/JCP.11m06831 #ICanHazPDF
.@TheLancetPsych This: appears to be a Chat-GPT copy of of our 2019 article:
Basically, everything needs to be improved to retain doctors in the UK.
Low Traffic Neighbourhoods deliver significant health benefits
